BR112023019301A2 - Formulações de vacina de coronavírus - Google Patents
Formulações de vacina de coronavírusInfo
- Publication number
- BR112023019301A2 BR112023019301A2 BR112023019301A BR112023019301A BR112023019301A2 BR 112023019301 A2 BR112023019301 A2 BR 112023019301A2 BR 112023019301 A BR112023019301 A BR 112023019301A BR 112023019301 A BR112023019301 A BR 112023019301A BR 112023019301 A2 BR112023019301 A2 BR 112023019301A2
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine formulations
- nanoparticles
- coronavirus vaccine
- coronavirus
- formulations
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 241000711573 Coronaviridae Species 0.000 title abstract 2
- 239000002105 nanoparticle Substances 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164487P | 2021-03-22 | 2021-03-22 | |
| US202163176825P | 2021-04-19 | 2021-04-19 | |
| US202163177059P | 2021-04-20 | 2021-04-20 | |
| US202163195986P | 2021-06-02 | 2021-06-02 | |
| US202163280395P | 2021-11-17 | 2021-11-17 | |
| US202163290439P | 2021-12-16 | 2021-12-16 | |
| US202163292196P | 2021-12-21 | 2021-12-21 | |
| US202163293468P | 2021-12-23 | 2021-12-23 | |
| PCT/US2022/020974 WO2022203963A1 (en) | 2021-03-22 | 2022-03-18 | Coronavirus vaccine formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023019301A2 true BR112023019301A2 (pt) | 2023-12-05 |
Family
ID=83396030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023019301A BR112023019301A2 (pt) | 2021-03-22 | 2022-03-18 | Formulações de vacina de coronavírus |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220332765A1 (https=) |
| EP (1) | EP4313143A4 (https=) |
| JP (1) | JP2024511412A (https=) |
| KR (1) | KR20230160349A (https=) |
| AU (1) | AU2022245141A1 (https=) |
| BR (1) | BR112023019301A2 (https=) |
| CA (1) | CA3213221A1 (https=) |
| IL (1) | IL306088A (https=) |
| MX (1) | MX2023011163A (https=) |
| TW (1) | TW202304955A (https=) |
| WO (1) | WO2022203963A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120227451A (zh) * | 2018-03-19 | 2025-07-01 | 诺瓦瓦克斯股份有限公司 | 多价流感纳米颗粒疫苗 |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| WO2023196634A2 (en) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| WO2024151583A2 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| WO2024258829A1 (en) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025054236A2 (en) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025088585A1 (en) * | 2023-10-25 | 2025-05-01 | Novavax AB | Saponin-based adjuvants and methods of characterizing same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968510B1 (en) * | 2013-03-14 | 2019-10-09 | President and Fellows of Harvard College | Nanoparticle-based compositions |
| US10953089B1 (en) * | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| US20210228707A1 (en) * | 2020-01-28 | 2021-07-29 | Modernatx, Inc. | Coronavirus rna vaccines |
| JP2023512519A (ja) * | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| US10906944B2 (en) * | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
-
2022
- 2022-03-18 CA CA3213221A patent/CA3213221A1/en active Pending
- 2022-03-18 EP EP22776366.1A patent/EP4313143A4/en active Pending
- 2022-03-18 JP JP2023558130A patent/JP2024511412A/ja active Pending
- 2022-03-18 MX MX2023011163A patent/MX2023011163A/es unknown
- 2022-03-18 AU AU2022245141A patent/AU2022245141A1/en active Pending
- 2022-03-18 IL IL306088A patent/IL306088A/en unknown
- 2022-03-18 WO PCT/US2022/020974 patent/WO2022203963A1/en not_active Ceased
- 2022-03-18 BR BR112023019301A patent/BR112023019301A2/pt unknown
- 2022-03-18 KR KR1020237036140A patent/KR20230160349A/ko active Pending
- 2022-03-22 TW TW111110461A patent/TW202304955A/zh unknown
- 2022-03-22 US US17/700,945 patent/US20220332765A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022245141A9 (en) | 2024-02-22 |
| JP2024511412A (ja) | 2024-03-13 |
| EP4313143A4 (en) | 2025-06-18 |
| AU2022245141A1 (en) | 2023-10-05 |
| CA3213221A1 (en) | 2022-09-29 |
| KR20230160349A (ko) | 2023-11-23 |
| US20220332765A1 (en) | 2022-10-20 |
| MX2023011163A (es) | 2024-02-27 |
| IL306088A (en) | 2023-11-01 |
| EP4313143A1 (en) | 2024-02-07 |
| TW202304955A (zh) | 2023-02-01 |
| WO2022203963A1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023019301A2 (pt) | Formulações de vacina de coronavírus | |
| BR112022014830A2 (pt) | Formulações de vacina para coronavírus | |
| MX2020011717A (es) | Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas. | |
| CY1121211T1 (el) | Εμβολιο ιου ερπητα ζωστηρα | |
| WO2006113214A3 (en) | Vaccine against pandemic strains of influenza viruses | |
| MX2024006589A (es) | Formulaciones de vacunas contra el coronavirus. | |
| BRPI1013780B8 (pt) | Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica | |
| AR041880A1 (es) | Composicion inmunogena | |
| AR065523A1 (es) | Procedimiento para fomentar una respuesta inmunitaria frente a un patogeno y composiciones | |
| PT1187629E (pt) | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador | |
| TW200722101A (en) | Novel composition | |
| CO6260103A2 (es) | Composiciones que comprenden antigenos neumococidos | |
| NO20021431L (no) | Intranasal influensavirus vaksine | |
| WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
| WO2007024941A3 (en) | Polyvalent vaccine | |
| CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
| AR061894A1 (es) | Vacunas para malaria | |
| WO2010019262A3 (en) | Polyvalent vaccine | |
| MX2013010620A (es) | Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo. | |
| MX388128B (es) | Vacuna combinada para cerdos. | |
| BR112015005056A2 (pt) | vacinas de combinação com sorogrupo b meningococcus e d/t/p | |
| BR112023021812A2 (pt) | Composição vacinal adjuvantada e métodos | |
| BR112013000394B8 (pt) | Composição imunogênica, uso da mesma e método para preparar a referida composição | |
| BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
| CY1112575T1 (el) | Βελτιωμενα αδρανοποιημενα εμβολια fcv |